Education
About Us
Working with TipRanks
Follow Us
Omeros Corporation (OMER)
:OMER
OMER Stock Chart & Stats
$7.52
-$0.23(-2.31%)
At close: 4:00 PM EST
$7.52
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$2.95 - $13.60
Previous CloseN/A
Volume193.12K
Average Volume (3M)5.93M
Market Cap
$475.71M
Enterprise ValueN/A
Total Cash (Recent Filing)$28.74M
Total Debt (Recent Filing)$184.33M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding68,055,824
10 Day Avg. Volume1,370,953
30 Day Avg. Volume5,932,676
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$13.12Price Target Upside74.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset Acquisition AgreementThe company provided details on a significant potential asset acquisition/licensing agreement that would provide OMER with an upfront payment of up to $150MM-$200MM, substantial development, regulatory and sales-based milestones and sales royalties.
Licensing Deal With Novo NordiskThe licensing deal with Novo Nordisk for the global rights of zaltenibart (OMS-906) includes a $240MM upfront payment as part of a potential total $2.1B agreement.
Pipeline ValidationThe transaction validates the potential in OMER’s broader pipeline earlier than anticipated.
Bears Say
FDA Approval SkepticismThere is skepticism of FDA approval of narsoplimab given the limited clinical dataset from open-label trials and the lack of new clinical data to support a positive regulatory decision.
Financial InstabilityThere is an urgent financial overhang that the company needs to address, indicating financial instability.
Uncertain FutureThere is an uncertain path forward for the company, contributing to the maintenance of a Hold rating.
Omeros News
OMER FAQ
What was Omeros Corporation’s price range in the past 12 months?
Omeros Corporation lowest stock price was $2.95 and its highest was $13.60 in the past 12 months.
What is Omeros Corporation’s market cap?
Omeros Corporation’s market cap is $475.71M.
When is Omeros Corporation’s upcoming earnings report date?
Omeros Corporation’s upcoming earnings report date is Mar 03, 2026 which is in 115 days.
How were Omeros Corporation’s earnings last quarter?
Currently, no data Available
Is Omeros Corporation overvalued?
According to Wall Street analysts Omeros Corporation’s price is currently Undervalued.
Does Omeros Corporation pay dividends?
Omeros Corporation does not currently pay dividends.
What is Omeros Corporation’s EPS estimate?
Omeros Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Omeros Corporation have?
Omeros Corporation has 68,055,824 shares outstanding.
What happened to Omeros Corporation’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Omeros Corporation?
Currently, no hedge funds are holding shares in OMER
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.12 (74.47% Upside)
$13.12 (74.47% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 61.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 58.8%
Last 30 Days ▲ 58.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.71%
Trailing 12-Months
Company Description
Omeros Corporation
Omeros Corporation (OMER) is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various medical conditions. The company operates primarily in the field of inflammation, coagulopathies, and central nervous system disorders. Omeros' lead product, Omidria, is used in cataract and lens replacement surgery to prevent intraoperative miosis and reduce postoperative ocular pain. Additionally, the company is engaged in multiple clinical-stage development programs targeting conditions such as complement-mediated diseases and addiction.
OMER Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a mostly positive outlook, with significant progress in financial restructuring and regulatory advancements for narsoplimab, despite some delays and decreased income from certain operations.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$13.12
▲(74.47% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
I-MAB
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.90% Insiders
7.22% Mutual Funds
0.09% Other Institutional Investors
80.34% Public Companies and Individual Investors